[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337642-105":59,"doc-detail-337642-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","activation-of-sting-by-the-novel-liposomal-tlc388-enhances-the-therapeutic-response-to-anti-pd-1-antibodies-in-combination-with-radiotherapy","Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy","","Immune checkpoint inhibitors show inconsistent clinical benefits in poorly immunogenic cancers such as microsatellite-stable colorectal cancer (MSS-CRC). The study demonstrates that the novel topoisomerase I inhibitor TLC388 remodels the tumor immune landscape and potentiates effects when combined with radiotherapy and immunotherapy. TLC388 triggers cytosolic single-stranded DNA accumulation for STING activation, inducing type I interferons to increase cancer immunogenicity, broaden dendritic cell and costimulatory infiltration, and deepen cytotoxic T and NK cell presence, resulting in superior therapeutic efficacy in poorly immunogenic MSS-CRC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/activation-of-sting-by-the-novel-liposomal-tlc388-enhances-the-therapeutic-response-to-anti-pd-1-antibodies-in-combination-with-radiotherapy/337642/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/activation-of-sting-by-the-novel-liposomal-tlc388-enhances-the-therapeutic-response-to-anti-pd-1-antibodies-in-combination-with-radiotherapy/337642.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are combination immunotherapies important for microsatellite-stable colorectal cancer (MSS-CRC)?","Question",{"text":112,"@type":113},"ICIs have limited effectiveness in MSS-CRC due to insufficient antitumor immunity. The study emphasizes the need to understand and develop combinational therapeutics for ICI-unresponsive cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does TLC388 activate STING in the proposed mechanism?",{"text":117,"@type":113},"TLC388 significantly triggers cytosolic single-stranded DNA (ssDNA) accumulation, which activates STING and leads to type I interferon production.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune changes are reported after TLC388 treatment, especially with radiotherapy and ICIs?",{"text":121,"@type":113},"TLC388-treated tumors show increased infiltration of dendritic cells, immune cells, and costimulatory molecules, along with more profound presence of cytotoxic T and NK cells when combined with radiotherapy and ICIs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337642,1790143707,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Cancer Immunology, Immunotherapy (2024) 73:92  \n[https://doi.org/10.1007/s00262-024-03692-8](https://doi.org/10.1007/s00262-024-03692-8)  \nRESEARCH  \nActivation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy  \nJhen-Yu Chen1,2 · Po-Yu Lin3 · Wei-Ze Hong3 · Pei-Chen Yang3 · Shu-Fen Chiang4 · Hsin-Yu Chang3 · Tao-Wei Ke5,6 · Ji-An Liang7,8 · William Tzu-Liang Chen5,9,10 · K. S. Clifford Chao3,7,8 · Kevin Chih-Yang Huang1,2,11  \nReceived: 26 January 2024 / Accepted: 25 March 2024 © The Author(s) 2024  \nAbstract  \nCurrent immune checkpoint inhibiters (ICIs) have contrasting clinical results in poorly immunogenic cancers such as microsatellite-stable colorectal cancer (MSS-CRC) . Therefore, understanding and developing the combinational therapeutics for ICI-unresponsive cancers is critical. Here, we demonstrated that the novel topoisomerase I inhibitor TLC388 can reshape the tumor immune landscape, corroborating their antitumor effects combined with radiotherapy as well as immunotherapy. We found that TLC388 significantly triggered cytosolic single-stranded DNA (ssDNA) accumulation for STING activation, leading to type I interferons (IFN-Is) production for increased cancer immunogenicity to enhance antitumor immunity. TLC388-treated tumors were infiltrated by a vast number of dendritic cells, immune cells, and costimulatory molecules, contributing to the favorable antitumor immune response within the tumor microenvironment. The infiltration of cytotoxic T and NK cells were more profoundly existed within tumors in combination with radiotherapy and ICIs, leading to superior therapeutic efficacy in poorly immunogenic MSS-CRC. Taken together, these results showed that the novel topoisomerase I inhibitor TLC388 increased cancer immunogenicity by ssDNA/STING-mediated IFN-I production, enhancing antitumor immunity for better therapeutic efficacy in combination with radiotherapy and ICIs for poorly immunogenic cancer.  \nKeywords Colorectal cancer · Topoisomerase I inhibitor · TLC388 · Antitumor immunity · STING  \n􀀍 K. S. Clifford Chao [094032@tool.caaumed.org.tw](094032@tool.caaumed.org.tw)  \n􀀍 Kevin Chih-Yang Huang [chihyang0425@mail.cmu.edu.tw](chihyang0425@mail.cmu.edu.tw)  \n1 Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung 40402, Taiwan  \n2 Translation Research Core, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan  \n3 Proton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan R.O.C.  \n4 Lab of Precision Medicine, Feng-Yuan Hospital, Ministry of Health and Welfare, Taichung 42055, Taiwan  \n5 Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan  \n6 School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan  \n7 Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan  \n8 Department of Radiation Oncology, School of Medicine, China Medical University, Taichung 40402, Taiwan  \n9 Department of Colorectal Surgery, China Medical University HsinChu Hospital, China Medical University, HsinChu  \n302, Taiwan  \n10 School of Medicine, China Medical University, Taichung 40402, Taiwan  \n11 Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung 40402, Taiwan  \n1 3  \nIntroduction  \nMalignant cells undergo evolutionary changes under immunosurveillance, leading to the development of tumors with the ability to escape and suppress the immune system [1] . Currently, effective strategies for overcoming immunosuppression and reinvigorating immune responses involve the use of immune checkpoint inhibitors (ICIs), such as antibodies targeting cytotoxic T lymphocyte antigen 4 (CTLA- 4), programmed cell death 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1) [2] . However, the","cbCaiedf02dKbFlL","https://ap.wps.com/l/cbCaiedf02dKbFlL","pdf",9616755,14,"English","# Introduction\n## Immune checkpoint inhibition and limitations\n## DNA damage, immunogenic cell death, and TOP1 inhibition\n## cGAS/STING signaling and rationale","[{\"question\":\"Why are combination immunotherapies important for microsatellite-stable colorectal cancer (MSS-CRC)?\",\"answer\":\"ICIs have limited effectiveness in MSS-CRC due to insufficient antitumor immunity. The study emphasizes the need to understand and develop combinational therapeutics for ICI-unresponsive cancers.\"},{\"question\":\"How does TLC388 activate STING in the proposed mechanism?\",\"answer\":\"TLC388 significantly triggers cytosolic single-stranded DNA (ssDNA) accumulation, which activates STING and leads to type I interferon production.\"},{\"question\":\"What immune changes are reported after TLC388 treatment, especially with radiotherapy and ICIs?\",\"answer\":\"TLC388-treated tumors show increased infiltration of dendritic cells, immune cells, and costimulatory molecules, along with more profound presence of cytotoxic T and NK cells when combined with radiotherapy and ICIs.\"}]","Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy | PDF",1790019965,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dc36a9c37de7c59d823f519ff93f6b2.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ed8489e1b8edb0b54060a563ab4b580.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9363c4a4ee94eb8775de79a0544fea2b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcf76c412f6722705d3d6b0f1db348b9.webp",980,1301]